Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, today announced that it will present four posters at IDWeek 2016™, which is being held from October 26 – 30 in New Orleans. Three posters will highlight data of ETX2514SUL, the combination of ETX2514, Entasis’ next-generation beta-lactamase inhibitor with an expanded spectrum of antimicrobial activity, and sulbactam, a beta-lactam with activity against Acinetobacter baumannii. ETX2514SUL is being developed as a potential therapy for multidrug-resistant A. baumannii infections.
“ETX2514 is the culmination of innovative chemistry and state-of-the-art structure-based design applied to targeting high-medical-need pathogens,” said Ruben Tommasi, Ph.D., Chief Scientific Officer of Entasis. “The data we are presenting illustrate our capabilities in translating innovative science into clinical programs.”
“The data from these recent studies further validate ETX2514SUL’s potential to treat serious, drug-resistant A. baumannii infections,” said Manos Perros, Ph.D., President and Chief Executive Officer of Entasis. “We are encouraged by these promising findings and remain committed to advancing ETX2514SUL in order to address this rapidly growing unmet medical need.”
All three of Entasis’ ETX2514SUL posters will be presented at the “New Antibiotics in Development” session on Saturday, October 29, 2016 from 12:30 – 2pm ET. Additional poster details are as follows:
Title: Global Surveillance of the Activity of Sulbactam combined
with the Novel β-lactamase Inhibitor ETX2514 against Clinical Isolates
of Acinetobacter baumannii from 2014
Poster Number: 2243
Overview: Exhibits ETX2514SUL’s potent in vitro bactericidal activity against 1,131 clinical isolates of A. baumannii, including meropenem-resistant, colistin-resistant and multidrug-resistant isolates.
Title: Human PK and Dose Projection of ETX2514 / Sulbactam
Combination for Use in the Treatment of Infections Caused by Acinetobacter
Poster Number: 2245
Overview: Outlines a predicted, potentially efficacious clinical dose regimen of ETX2514SUL based on translation of non-clinical studies.
Title: Sulbactam combined with the Novel β-lactamase Inhibitor
ETX2514 for the Treatment of Multidrug-resistant Acinetobacter
Poster Number: 2246
Overview: Characterizes the mechanism of action of ETX2514SUL in A. baumannii.
In addition to the ETX2514SUL posters, data on ETX0914, Entasis’ novel oral antibiotic being developed for the treatment of uncomplicated gonorrhea, will be presented in a fourth poster at the “Clinical Infectious Disease: Sexually Transmitted Infections” session on Friday, October 28, 2016 from 12:30 – 2pm ET. Research on ETX0914 is supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Additional poster details are as follows:
Title: Microbiological Cure Rates and Antimicrobial
Susceptibility of Neisseria gonorrhoeae to ETX0914 (AZD0914) in a
Phase II Treatment Trial for Urogenital Gonorrhea
Poster Number: 1308
ETX2514 is a potent and broad spectrum inhibitor of class A, C, and D beta-lactamases. A. baumannii is a Gram-negative bacterium that causes severe infections which are associated with high mortality. A. baumannii infections are frequently multi-drug resistant and there is an urgent need to identify new safe and effective agents to treat affected patients. Sulbactam is a generic beta-lactam which has intrinsic activity against A. baumannii but suffers from widespread beta-lactamase-mediated resistance. In preclinical studies, ETX2514 restores sulbactam’s antimicrobial activityagainst A. baumannii. Entasis Therapeutics is developing ETX2514SUL, the combination of ETX2514 and sulbactam, for the treatment of severe A. baumannii infections. ETX2514SUL is currently in Phase 1 clinical trials.
ETX0914 is a novel oral antibiotic for the treatment of uncomplicated gonorrhea and the first of a novel class of molecules to be developed for this indication. Uncomplicated gonorrhea has become increasingly difficult to treat as the Neisseria gonorrhoeae bacterium developed resistance to successive classes of antibiotics, leaving only one injectable cephalosporin, ceftriaxone, as a recommended first-line therapy. As a result, the Centers for Disease Control and Prevention has recently designated N. gonorrhoeae an urgent public health threat that requires aggressive action.
Uncomplicated gonorrhea infections carry high morbidity, enhance transmission of other sexually transmitted diseases, and are highly stigmatized. ETX0914 has potent in vitro activity against N. gonorrhoeae, including isolates resistant to fluoroquinolones and extended spectrum cephalosporins, and achieved its primary endpoint in a recent Phase 2 clinical study. ETX0914 has been designated a Qualified Infectious Disease Product (QIDP) by the U.S. Food and Drug Administration and awarded Fast Track status.
About Entasis Therapeutics Inc.
Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of fundamentally innovative clinical and preclinical anti-infective programs is designed to revolutionize the way physicians treat serious bacterial diseases. www.entasistx.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161028005112/en/Business Wire
Last updated on: 28/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.